^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ERBB3 expression

    i
    Other names: ERBB3, HER3, LCCS2, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
    Entrez ID:
    2065
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    10ms
    Patritumab deruxtecan displayed manageable safety & produced responses in heavily pretreated patients w/ ER+ orTNBC breast cancer with varying levels of HER3 expression. @ErikaHamilton9 @SarahCannonDocs #ASCO23 #bcsm https://t.co/yWwZuEMOTb (@OncLive)
    Clinical
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    |
    patritumab deruxtecan (U3-1402)
    10ms
    Patritumab deruxtecan displayed manageable safety & produced responses in heavily pretreated patients w/ ER+ orTNBC breast cancer with varying levels of HER3 expression. @ErikaHamilton9 @SarahCannonDocs #ASCO23 #bcsm https://t.co/KDo6n5PeJF (@OncLive)
    Clinical
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    |
    patritumab deruxtecan (U3-1402)
    11ms
    #ASCO23 #BreastCancer #OncoAlert Take Home Message 3 Non-CDK series. TROPiCS-02: Final OS analysis. SG extended the 3-year OS by 4.6 M. A significant difference in 1-year OS. HER3-DXd: Phase II trial. HER3 expression correlates with ORR and CBR but is not a predictive factor.… https://t.co/lEFwjXZzya (@teamoncology)
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    |
    patritumab deruxtecan (U3-1402)
    11ms
    #ASCO23 #BreastCancer #OncoAlert Take Home Message 3 Non-CDK series. TROPiCS-02: Final OS analysis. SG extended the 3-year OS by 4.6 months. A significant difference in 1-year OS. HER3-Dxd: Phase II trial. HER3 expression correlates with ORR and CBR but is not a predictive… https://t.co/FKqBIf4drP (@teamoncology)
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    |
    patritumab deruxtecan (U3-1402)
    12ms
    also, stay tuned for this mini-oral from my group! 3MO - HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial (ID 48) @_SOLTI… https://t.co/rfUtZabNh8 (@prat_aleix)
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 positive • HR positive • HER-2 negative • HER-2 expression • ERBB3 expression • HR positive + HER-2 negative
    |
    patritumab deruxtecan (U3-1402)
    over1year
    https://t.co/id1APCulbd Patritumab deruxtecan also with activity in non-EGFR mutated NSCLC. I suspect a lot of bystander effect with these ADCs (including those targeting TROP2). Mutation presence or level of expression (HER3 or TROP2) seems to be less important…so far. (@ryangentzler)
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • TROP2 (Trophoblast Cell Surface Antigen 2)
    |
    EGFR mutation • ERBB3 expression • ERBB3 mutation
    |
    patritumab deruxtecan (U3-1402)
    almost2years
    Patritumab deruxtecan (HER3 ADC) in metastatic breast cancer that was HER3+ (113 HR+, 53 TNBC, 14 HER2+) ORR HR+ 30%, 23% TNBC, 43% HER2+ HER3 expression dynamic. 6.6% ILD #ASCO22 @OncoAlert (@stolaney1)
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    |
    patritumab deruxtecan (U3-1402)
    almost2years
    Krop Patritumab DxD, cont. ORR 30% for ER-pos, 23% for TNBC, 40% for HER2 pos. No obvious relation to degree of HER3 expression, which was dynamic over time. Interesting early data for a novel ADC. Pneumonitis/ILD seen, unsurprisingly. (@GeorgeSledge51)
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    almost2years
    HER3 expression noted in very similar population, HR+ HER2- MBC, by T-DXd and Sacituzumab. Also we need to remember that patritumab alone did not have any clinical activity, the efficacy of this ADC, linker and payload dependent. #ASCO22 @OncoAlert (@teamoncology)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 negative • ERBB3 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • patritumab (U3-1287)
    almost2years
    #ASCO2022 Krop Phase 1/2 study of patritumab deruxtecan, a HER3-directed ADC in HER3-expressing MBC. Same tox as T-DxD. Ongoing study. 2-6 prior lines of CT, 1-2 in TNBC. (@GeorgeSledge51)
    P1/2 data
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • patritumab deruxtecan (U3-1402)
    almost2years
    Think her3 expression did not matter in NSCLC , wonder when HERTHENA 01 is reporting.. (@RenoHemonc)
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    over2years
    Preclinical data on #HER3 in #EGFR+ NSCLC @CCR_AACR. EGFR TKI increased HER3 expression and enhanced activity of HER3-DXd (patritumab deruxtecan). Early clinical data already show HER3-DXd can overcome resistance. Role in 1L to prevent resistance? #LCSM https://t.co/FjITR5Qs6P (@StephenVLiu)
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR expression • ERBB3 expression
    |
    patritumab deruxtecan (U3-1402)
    over2years
    Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mutant NSCLC post-TKI. Encouraging RR 39%, mPFS 8.2m across various mechanisms of TKI resistance and HER3 expression levels. #LCSM https://t.co/Ig3P6PYWdf (@StephenVLiu)
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • ERBB3 expression
    |
    patritumab deruxtecan (U3-1402)
    over2years
    The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer @eugeneahn @CancerCenter @ASCO #ASCO21 #gyncsm https://t.co/9n2OmzcUwy (@OncLive)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 amplification • HER-2 mutation • HER-2 expression • ERBB3 expression • ERBB3 mutation
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    almost3years
    The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer. @eugeneahn @CancerCenter @ASCO #ASCO21 #gyncsm https://t.co/ObnExyFHoZ (@OncLive)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 amplification • HER-2 mutation • HER-2 expression • ERBB3 expression • ERBB3 mutation
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    almost3years
    HER3-DxD ADC achieves ORR 37%, DCR 72% with mPFS of 8.2 m in heavily pretreated EGFR+ #LCSM (>80% post-osi). Activity not correlated with HER3 expression, AE: hematological toxicity, ILD 7%, dose reduction21% #ASCO21 (@jsoriamd)
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    almost3years
    HER3-TxD Ph1 post TKI expansion cohort by Dr Janne; ORR 39%; mPFS=8.2mo; efficacy observed across diverse resistance mechanisms; systemic responses in pts with CNS mets; HER3 expression not predictive #ASCO21 #LCSM (@DrSanjayPopat)
    Clinical
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    3years
    #WCLC20 Fairly heavily pretreated population with both TKI and chemotherapy and many with IO as well. Biopsy required for HER3 expression (violin plot on right) and nearly all were HER3 positive. #LCSM (@StephenVLiu)
    Clinical
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    3years
    The patients on the trial had multiple prior lines of therapy. There was a wide range of HER3 expression, but enrollment did not depend on HER3 expression. #LCSM #WCLC20 (@Jbauml)
    Clinical
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    3years
    HER3-Dxd shows encouraging activity in EGFRm #lungcancer with both on-target and off-target mechanisms of resistance. Nearly all tumors expressed some level of HER3. #WCLC20 @EGFRResisters (@ryangentzler)
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    3years
    #WCLC20 @IASLC @OncoAlert Efficacy of Patritumab-Dx in #EGFRMT #NSCLC. HER3 was expressed in nearly all tumors. Efficacy was observed in EGFR C797S, MET amplification, HER2 MT BRAF fusion, and PIK3CA MT. @HelenaYu923 @EGFRResisters (@CharuAggarwalMD)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 amplification • MET amplification • ERBB3 expression • EGFR C797S • BRAF fusion • BRAF amplification
    |
    patritumab (U3-1287)
    3years
    #WCLC20 At baseline, nearly all tumor expressed HER3 independent of when #EGFR TKI was stopped. Some association with expression and efficacy. I always feel this should be a stronger association given how I think ADCs work but maybe I don't know how ADCs work. #LCSM (@StephenVLiu)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    over3years
    U3-1402 HER-3 ADC spotlight 🔆 presentation ✳️ORR 30.3% ✳️mPFS 8.4 months, no difference by HER-3 expression ⚠️1 fatal pneumonitis ❓is HER-3 expression needed? #SABCS20 @OncoAlert #bcsm (@ErikaHamilton9)
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    |
    patritumab deruxtecan (U3-1402)
    over3years
    More on #SABCS20 Keep an 👀 on these abstracts: 👉first report of T-Dxd+nivo in #HER2-expressing BC ➡️strong rationale for the combo, important to check ILD rate 👉update of patritumab DxD in #HER3-expressing BC ➡️ 43% ORR previously reported, survival outcomes pending #bcsm (@PTarantinoMD)
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 expression • ERBB3 expression
    |
    Opdivo (nivolumab) • patritumab (U3-1287)
    over3years
    #ESMO20 HER3 is expressed in 80% of #EGFR mutant NSCLC hence this ADC approach. Patritumab is an ADC with HER3 Ab linked to a topoisomerase I payload. Here, data from escalation (n=12) and expansion (n=45) in EGFR+ NSCLC after TKI (expansion was post chemo as well). #LCSM (@StephenVLiu)
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • EGFR expression • ERBB3 expression • ERBB3 mutation
    |
    patritumab (U3-1287)
    almost4years
    I agree. “An extended biomarker panel could identify right- & rectal-PTL (primary tumor location) pts who have good effect from panitumumab”. Some pts ē right-sided tumors do derive benefit to EGFR⛔️. 👆🏾 🟩epiregulin/amphiregulin EREG/AREG 🟩HER3 expression #WORLDGI2020 #CRCSM (@pashtoonkasi)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • AREG (Amphiregulin) • EREG (Epiregulin)
    |
    ERBB3 expression
    |
    Vectibix (panitumumab)